Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.
Supiot S, Rousseau C, Dore M, Cheze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Supiot S, et al. Among authors: dore m. Oncotarget. 2018 Jan 13;9(11):10005-10015. doi: 10.18632/oncotarget.24234. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515786 Free PMC article.
Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S. Goineau A, et al. Among authors: dore m. PLoS One. 2018 Apr 9;13(4):e0194173. doi: 10.1371/journal.pone.0194173. eCollection 2018. PLoS One. 2018. PMID: 29630602 Free PMC article.
Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.
Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, Rio E, Milano GA, Mahier-Ait Oukhatar C, Carrie C. Supiot S, et al. Among authors: dore m. Oncotarget. 2018 Apr 24;9(31):22147-22157. doi: 10.18632/oncotarget.25189. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774129 Free PMC article.
Reoxygenation during radiotherapy in intermediate-risk prostate cancer.
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Supiot S, et al. Among authors: dore m. Radiother Oncol. 2019 Apr;133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12. Radiother Oncol. 2019. PMID: 30935573
Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
Goineau A, Campion L, Commer JM, Vié B, Ghesquière A, Béra G, Jaffres D, Magné N, Artignan X, Chamois J, Bergerot P, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, De Decker L, Supiot S. Goineau A, et al. Among authors: dore m. Cancers (Basel). 2020 Mar 9;12(3):635. doi: 10.3390/cancers12030635. Cancers (Basel). 2020. PMID: 32182949 Free PMC article.
521 results